GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NAYA Biosciences (NAS:NAYA) » Definitions » Piotroski F-Score

NAYA (NAYA Biosciences) Piotroski F-Score : 4 (As of Dec. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is NAYA Biosciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NAYA Biosciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for NAYA Biosciences's Piotroski F-Score or its related term are showing as below:

NAYA' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 6
Current: 4

During the past 13 years, the highest Piotroski F-Score of NAYA Biosciences was 6. The lowest was 1. And the median was 4.


NAYA Biosciences Piotroski F-Score Historical Data

The historical data trend for NAYA Biosciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NAYA Biosciences Piotroski F-Score Chart

NAYA Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 4.00 4.00 1.00 3.00

NAYA Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 3.00 4.00 6.00 4.00

Competitive Comparison of NAYA Biosciences's Piotroski F-Score

For the Medical Devices subindustry, NAYA Biosciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NAYA Biosciences's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NAYA Biosciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where NAYA Biosciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -1.995 + -1.597 + -2.245 + -1.631 = $-7.47 Mil.
Cash Flow from Operations was -0.715 + -0.261 + -1.456 + -0.641 = $-3.07 Mil.
Revenue was 1.382 + 1.576 + 1.837 + 1.433 = $6.23 Mil.
Gross Profit was 0.495 + 0.726 + 0.975 + 0.445 = $2.64 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(19.476 + 18.506 + 18.318 + 18.032 + 17.019) / 5 = $18.2702 Mil.
Total Assets at the begining of this year (Sep23) was $19.48 Mil.
Long-Term Debt & Capital Lease Obligation was $3.39 Mil.
Total Current Assets was $1.96 Mil.
Total Current Liabilities was $8.66 Mil.
Net Income was -2.767 + -2.551 + -2.241 + -1.248 = $-8.81 Mil.

Revenue was 0.278 + 0.348 + 0.316 + 0.975 = $1.92 Mil.
Gross Profit was 0.044 + 0.117 + 0.08 + 0.394 = $0.64 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(4.678 + 3.71 + 6.151 + 6.639 + 19.476) / 5 = $8.1308 Mil.
Total Assets at the begining of last year (Sep22) was $4.68 Mil.
Long-Term Debt & Capital Lease Obligation was $6.72 Mil.
Total Current Assets was $1.79 Mil.
Total Current Liabilities was $4.88 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NAYA Biosciences's current Net Income (TTM) was -7.47. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NAYA Biosciences's current Cash Flow from Operations (TTM) was -3.07. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-7.468/19.476
=-0.38344629

ROA (Last Year)=Net Income/Total Assets (Sep22)
=-8.807/4.678
=-1.88264215

NAYA Biosciences's return on assets of this year was -0.38344629. NAYA Biosciences's return on assets of last year was -1.88264215. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

NAYA Biosciences's current Net Income (TTM) was -7.47. NAYA Biosciences's current Cash Flow from Operations (TTM) was -3.07. ==> -3.07 > -7.47 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=3.387/18.2702
=0.18538385

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=6.717/8.1308
=0.82611797

NAYA Biosciences's gearing of this year was 0.18538385. NAYA Biosciences's gearing of last year was 0.82611797. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=1.957/8.655
=0.22611207

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=1.792/4.884
=0.36691237

NAYA Biosciences's current ratio of this year was 0.22611207. NAYA Biosciences's current ratio of last year was 0.36691237. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

NAYA Biosciences's number of shares in issue this year was 3.886. NAYA Biosciences's number of shares in issue last year was 1.777. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2.641/6.228
=0.42405267

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.635/1.917
=0.33124674

NAYA Biosciences's gross margin of this year was 0.42405267. NAYA Biosciences's gross margin of last year was 0.33124674. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=6.228/19.476
=0.31977819

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=1.917/4.678
=0.40979051

NAYA Biosciences's asset turnover of this year was 0.31977819. NAYA Biosciences's asset turnover of last year was 0.40979051. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NAYA Biosciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.

NAYA Biosciences  (NAS:NAYA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


NAYA Biosciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of NAYA Biosciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NAYA Biosciences Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
NAYA Biosciences operates a healthcare services fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880